Previous clinical trials have failed to conclude whether preoperative infliximab increases early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. A meta-analysis including 13 studies and 2,933 patients has now confirmed that preoperative infliximab therapy has no significant effect on the rate of infectious or noninfectious complications in these patients (P = 0.81 and P = 0.61, respectively).